Proteins and Peptides

05 Aug 2019 INmune Bio Reports Positive Preliminary Data from INB03 Phase I Clinical Trial in Cancer
05 Aug 2019 Antidote Therapeutics Progresses Optimization of the Nicotine-degrading Enzyme, NicA2, for Potential Use in Treating Nicotine Addiction
31 Jul 2019 Medicenna Selects its Lead Immuno-Oncology Clinical Candidate, MDNA19, from its IL-2 Superkine Platform
29 Jul 2019 Rhythm Pharmaceuticals Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for Setmelanotide for the Treatment of Bardet-Biedl Syndrome
25 Jul 2019 BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA
24 Jul 2019 Synthorx Initiates Patient Dosing in Australia and Announces Clearance of IND in the U.S. for Lead Immuno-oncology Product Candidate, THOR-707
21 Jul 2019 Ascendis Pharma Announces Filing of Investigational New Drug (IND) Application for Initiation of a Global Phase 2 Trial for TransCon™ CNP in Children with Achondroplasia
16 Jul 2019 Ambrx to receive milestone payment from Bristol-Myers Squibb for the initiation of Phase 1 Clinical Trial of a long-acting Relaxin derivative
16 Jul 2019 Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria and Guides to Next Phase of Development
11 Jul 2019 SOTIO Initiates First-In-Human Clinical Trial with IL-15 Superagonist SO-C101
09 Jul 2019 Dermata Therapeutics Announces Positive Results from a Phase 1 Clinical Trial of DMT410, A New Topical Delivery Mechanism for Botulinum Toxin
08 Jul 2019 Catalyst Biosciences Meets the Primary Endpoint of Reduction in Annualized Bleeding Rate in the Phase 2 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Patients with Hemophilia A or B with Inhibitors
08 Jul 2019 Aravive Announces Independent Data Monitoring Committee Recommends Continuation of Phase Ib Study of AVB-500 In Recurrent Platinum Resistant Ovarian Cancer After Review of First Two Cohorts of Patients
08 Jul 2019 New data show nonacog beta pegol (N9-GP) is effective and well tolerated for the prevention and treatment of bleeding in children with haemophilia B
08 Jul 2019 Interim Data Evaluating Elocta® for Immune Tolerance Induction in People With Inhibitors and Severe Haemophilia A Shared at ISTH 2019
08 Jul 2019 Takeda Unveil New Data from the PROPEL Study at ISTH 2019, Reinforcing the Potential Benefit for Personalized Prophylaxis with ADYNOVATE in Severe Hemophilia A
07 Jul 2019 Octapharma communicates an update on the development of SubQ-8, a novel subcutaneous recombinant FVIII, at ISTH 2019
04 Jul 2019 Akero Therapeutics Announces Dosing of First Patient in Phase 2a Study of AKR-001 to Treat NASH (BALANCED)
03 Jul 2019 Orion Biotechnology's CCR5 Blocker OB-002 Shows Strong Efficacy in a New Preclinical Model of Multiple Sclerosis
01 Jul 2019 La Jolla Pharmaceutical Company Receives Positive CHMP Opinion for GIAPREZA™ (angiotensin II) for the Treatment of Refractory Hypotension in Adults with Septic or Other Distributive Shock
01 Jul 2019 Oxurion NV Reports Positive Topline Phase 1 Results with THR-149, a novel, potent plasma kallikrein inhibitor for the treatment of DME
27 Jun 2019 Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Developmental Ready-to-use Glucagon in Patients at Risk From Hypoglycemia Following Bariatric Surgery
27 Jun 2019 ERYTECH Announces Enrollment of First Patient in Phase 2 Clinical Trial Evaluating Eryaspase in TNBC
26 Jun 2019 Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome
25 Jun 2019 Dompé Announces First Patient Enrollment in Phase 2b Clinical Trial Investigating Novel Mechanism of Action in Moderate to Severe Dry Eye Disease

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top